Brief: Bavarian Nordic Receives U.S. FDA Approval Of Chikungunya Vaccine For Persons Aged 12 And Older
14/02/2025 22:28
Feb 14 (Reuters) - Bavarian Nordic A/S BAVA.CO :
* REG-BAVARIAN NORDIC RECEIVES U.S. FDA APPROVAL OF
CHIKUNGUNYA
VACCINE FOR PERSONS AGED 12 AND OLDER
* BAVARIAN NORDIC A/S - VIMKUNYA TO BE COMMERCIALLY
AVAILABLE IN
U.S. IN FIRST HALF OF 2025
* BAVARIAN NORDIC A/S - VIMKUNYA TO BE LAUNCHED IN KEY
EUROPEAN
MARKETS IN FIRST HALF OF 2025
Source text: ID:nGNE3NsD5w
Further company coverage: BAVA.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract
Brief: Bavarian Nordic Secures Additional Government Contract For The Supply Of Smallpox/Mpox Vaccine
Brief: Bavarian Nordic Launches Final Tranche Of Buy-Back Program
Bavarian Nordic falls as high costs, lower vaccine sales hit Q1 results
Bavarian Nordic Q1 revenue falls as Public Preparedness unit sales decline